国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (2): 95-98.doi: 10.3760/cma.j.issn.1673-422X.2017.02.004

• 论著 • 上一篇    下一篇

不同化疗方案联合放疗对合并2型糖尿病非小细胞肺癌患者疗效的影响

张晓飞,魏亚强   

  1. 716000 陕西省延安市人民医院肿瘤科（张晓飞），呼吸科（魏亚强）
  • 出版日期:2017-02-08 发布日期:2017-01-04
  • 通讯作者: 魏亚强，Email: 13379530708@163.com E-mail:13379530708@163.com

Effect of different chemotherapy combined with radiotherapy for the treatment of nonsmall cell lung cancer complicated with type 2 diabetes

Zhang Xiaofei, Wei Yaqiang   

  1. Department of Oncology, Yan′an People′s Hospital, Shaanxi Province, Yan′an 716000, China
  • Online:2017-02-08 Published:2017-01-04
  • Contact: Wei Yaqiang E-mail:13379530708@163.com

PDF

881

被引次数

3

摘要： 目的探讨不同化疗方案联合放疗对合并2型糖尿病中晚期非小细胞肺癌（NSCLC）患者疗效及不良反应发生率的影响。方法选取合并2型糖尿病的中晚期NSCLC患者123例，通过计算机产生随机数分为A、B、C 3组，均41例。3组患者均接受三维适形放疗，同步进行化疗，A组给予吉西他滨联合顺铂，B组给予紫杉醇联合顺铂，C组给予培美曲塞联合顺铂。观察比较3组患者的治疗有效率、肿瘤进展时间、中位生存期、生存率以及不良反应发生率。结果A组、B组和C组患者的总有效率分别为82.93%、78.05%和80.49%，差异无统计学意义（χ2=0.365，P=0.357）。3组患者肿瘤进展时间分别为（6.54±1.23）个月、（5.96±1.27）个月、（6.27±1.08）个月，差异无统计学意义（F=1.235，P=0.314）；中位生存期分别为（16.54±1.87）个月、（15.36±1.25）个月、（16.29±2.08）个月，差异无统计学意义（F=2.226，P=0.245）；1年生存率分别为80.49%、82.93%、85.37%，差异无统计学意义（χ2=1.234，P=0.665）；2年生存率分别为48.78%、51.22%、43.90%，差异无统计学意义（χ2=2.354，P=0.451）。C组患者放射性肺炎发生率为24.39%，骨髓抑制发生率为24.39%，显著低于B组的31.71%、53.66%（χ2=18.687，P=0.017；χ2=25.336，P=0.011）及A组的41.46%、31.71%（χ2=17.543，P=0.019；χ2=24.358，P=0.013）。结论3组患者的临床疗效相似，但培美曲塞和顺铂联合放疗组患者的不良反应发生率最低，临床可采用培美曲塞联合顺铂作为初治NSCLC患者的安全有效药物进行治疗。

关键词: 癌, 非小细胞肺, 糖尿病, 2型, 放射疗法, 药物疗法, 不良反应

Abstract: Objective  To evaluate the effect and the incidence of adverse reaction of different chemotherapy combined with radiotherapy for the treatment of nonsmall cell lung cancer (NSCLC) complicated with type 2 diabetes. MethodsA total of 123 midterm advanced NSCLC patients complicated with type 2 diabetes were randomly divided into A, B, C three groups through the random number generated by computer, and each group was 41 cases. Three groups of patients were treated with threedimensional conformal radiotherapy and synchronous chemotherapy. Group A received gemcitabine and cisplatin, group B received paclitaxel and cisplatin, and group C received pemetrexed and cisplatin. The treatment efficiency, time to tumor progression, median survival time, survival rate and incidence of adverse reaction were observed and compared. ResultsThe total effective rates of group A, B and C were 82.93%, 78.05% and 80.49%, with no statistically significant difference (χ2=0.365, P=0.357). The times to tumor progression of the three groups were (6.54±1.23) months, (5.96±1.27) months, (6.27±1.08) months, with no statistically significant difference (F=1.235,P=0.314); the median survival times of the three groups were (16.54±1.87) months, (15.36±1.25) months, (16.29±2.08) months respectively, with no statistically significant difference (F=2.226, P=0.245); 1year survival rates of the three groups were 80.49%, 82.93%, 85.37% respectively, with no statistically significant difference (χ2=1.234, P=0.665); 2year survival rates were 48.78%, 51.22%, 43.90%, with no statistically significant difference (χ2=2.354, P=0.451). The incidence rates of radioactive pneumonia and bone marrow suppression in group C were 24.39% and 24.39%, those were significantly lower than 31.71%, 53.66% of group B (χ2=18.687, P=0.017; χ2=25.336, P=0.011) and 41.46%, 31.71% of group A (χ2=17.543, P=0.019;χ2=24.358, P=0.013). ConclusionThe clinical efficacy of the three groups are similar, but the incidence rate of adverse reaction in pemetrexed and cisplatin plus radiotherapy group is the lowest. Therefore, pemetrexed plus cisplatin is the safe and effective treatment for the previously untreated patients with NSCLC.

Key words: Carcinoma, nonsmallcell lung; Diabetes mellitus, type 2, Radiotherapy, Drug therapy, Adverse reaction